Beacon Capital Management LLC (Tennessee)’s GSK GSK Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-366	Closed	-$14.1K	–	488
2025 Q2	$14.1K	Sell	366 -176	-32%	-$6.72K	﹤0.01%	564
2025 Q1	$21K	Buy	542 +152	+39%	+$5.57K	﹤0.01%	473
2024 Q4	$13.2K	Buy	390 +157	+67%	+$5.65K	﹤0.01%	551
2024 Q3	$9.53K	Sell	233 -29	-11%	-$1.19K	﹤0.01%	658
2024 Q2	$10.1K	Hold	262	–	–	﹤0.01%	567
2024 Q1	$11.2K	Hold	262	–	–	﹤0.01%	556
2023 Q4	$9.5K	Sell	262 -51	-16%	-$1.83K	﹤0.01%	536
2023 Q3	$11.2K	Hold	313	–	–	﹤0.01%	536
2023 Q2	$11.2K	Buy	313 +199	+175%	+$7.14K	﹤0.01%	536
2023 Q1	$4.06K	Sell	114 -170	-60%	-$5.95K	﹤0.01%	671
2022 Q4	$9.98K	Sell	284 -113	-28%	-$3.76K	﹤0.01%	512
2022 Q3	$17K	Sell	397 -241	-38%	-$9.13K	0.01%	378
2022 Q2	$35K	Hold	638	–	–	0.01%	295
2022 Q1	$35K	Buy	+638	New	+$34.7K	0.01%	295

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s GSK Position: Q3 2025 in Review

Beacon Capital Management LLC (Tennessee) sold out of GSK (GSK) in Q3 2025, closing a stake of 366 shares — an estimated $14.1K sold.

Beacon Capital Management LLC (Tennessee) first reported a position in GSK in Q1 2022 and held it in 14 quarters. The position peaked at $35K in Q2 2022. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

Beacon Capital Management LLC (Tennessee) reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
Beacon Capital Management LLC (Tennessee) sold 366 GSK shares in Q3 2025, an estimated $14.1K.
Beacon Capital Management LLC (Tennessee) first reported a position in GSK in Q1 2022 and held it in 14 quarters.
Beacon Capital Management LLC (Tennessee)'s GSK position peaked at $35K in Q2 2022.
895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q3 2025, filed 7 Nov 2025.